Index -
P/E 15.11
EPS (ttm) 1.78
Insider Own 15.01%
Shs Outstand 446.69M
Perf Week -1.97%
Market Cap 12.17B
Forward P/E 6.14
EPS next Y 4.38
Insider Trans -1.16%
Shs Float 384.11M
Perf Month -4.57%
Income 798.52M
PEG 4.72
EPS next Q 0.99
Inst Own 68.84%
Short Float 3.45%
Perf Quarter -10.54%
Sales 2.24B
P/S 5.44
EPS this Y -13.53%
Inst Trans 1.54%
Short Ratio 4.95
Perf Half Y -7.87%
Book/sh 14.41
P/B 1.87
EPS next Y 13.18%
ROA 4.82%
Short Interest 13.25M
Perf Year -16.27%
Cash/sh 1.93
P/C 13.96
EPS next 5Y 3.20%
ROE 12.84%
52W Range 25.92 - 33.86
Perf YTD -4.17%
Dividend Est. 0.92 (3.40%)
P/FCF 4.62
EPS past 5Y 2.23%
ROI 6.32%
52W High -20.50%
Beta 0.47
Dividend TTM 0.82 (3.05%)
Quick Ratio 12.52
Sales past 5Y 5.78%
Gross Margin -
52W Low 3.86%
ATR (14) 0.56
Dividend Ex-Date May 16, 2024
Current Ratio 12.52
EPS Y/Y TTM 135.14%
Oper. Margin 41.97%
RSI (14) 42.52
Volatility 2.02% 2.02%
Employees 89
Debt/Eq 0.94
Sales Y/Y TTM -5.12%
Profit Margin 35.67%
Recom 1.22
Target Price 44.01
Option/Short Yes / Yes
LT Debt/Eq 0.94
EPS Q/Q -98.61%
Payout 31.57%
Rel Volume 0.66
Prev Close 27.20
Sales Surprise -0.29%
EPS Surprise -0.92%
Sales Q/Q -16.96%
Earnings May 09 BMO
Avg Volume 2.67M
Price 26.92
SMA20 -0.67%
SMA50 -3.25%
SMA200 -4.88%
Trades
Volume 1,763,793
Change -1.03%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-03-24 Downgrade
UBS
Buy → Neutral
$28
Jun-14-22 Resumed
UBS
Buy
$47
May-13-22 Initiated
Scotiabank
Sector Outperform
$53
Apr-27-22 Initiated
Goldman
Buy
$56
Apr-14-22 Upgrade
JP Morgan
Neutral → Overweight
$50
Apr-06-22 Resumed
Morgan Stanley
Overweight
$48
Oct-29-21 Upgrade
Citigroup
Neutral → Buy
$50
Jul-30-21 Initiated
Tigress Financial
Buy
$50
Nov-09-20 Upgrade
UBS
Neutral → Buy
$52 → $51
Jul-14-20 Initiated
Evercore ISI
In-line
Jul-13-20 Initiated
UBS
Neutral
$52
Jul-13-20 Initiated
SunTrust
Buy
$56
Jul-13-20 Initiated
Morgan Stanley
Equal-Weight
$51
Jul-13-20 Initiated
JP Morgan
Neutral
$50
Jul-13-20 Initiated
Goldman
Neutral
$47
Jul-13-20 Initiated
Cowen
Outperform
$55
Jul-13-20 Initiated
Citigroup
Neutral
$50
Jul-13-20 Initiated
BofA Securities
Buy
$55
Show Previous Ratings
Jun-05-24 06:14AM
Jun-04-24 04:15PM
Jun-03-24 05:15PM
May-28-24 07:10AM
May-27-24 06:28PM
11:10PM
Loading…
May-25-24 11:10PM
May-22-24 04:10PM
04:00PM
May-20-24 02:41PM
May-13-24 08:15AM
May-10-24 01:07AM
May-09-24 03:35PM
12:00PM
11:56AM
10:46AM
08:10AM
Loading…
08:10AM
07:00AM
06:45AM
May-08-24 08:51AM
May-06-24 09:16AM
May-02-24 04:01PM
10:01AM
Apr-30-24 08:37AM
Apr-19-24 08:15AM
Apr-17-24 08:15AM
Mar-17-24 08:50AM
Feb-28-24 04:15PM
Feb-20-24 12:45PM
Feb-17-24 12:15AM
Feb-16-24 03:30PM
09:45AM
Loading…
09:45AM
12:04AM
Feb-15-24 11:08PM
07:58AM
07:30AM
Jan-31-24 01:04AM
Jan-30-24 04:15PM
Jan-19-24 08:15AM
Jan-08-24 07:00AM
Dec-18-23 05:30AM
Nov-27-23 04:15PM
Nov-13-23 08:10AM
08:00AM
Nov-09-23 04:33PM
12:15AM
Nov-08-23 07:00AM
Oct-19-23 07:59AM
Oct-16-23 04:15PM
Oct-11-23 04:15PM
Sep-21-23 08:25AM
Sep-05-23 04:15PM
04:01PM
08:25AM
Aug-24-23 06:30AM
Aug-08-23 07:00AM
Jul-18-23 04:15PM
Jul-17-23 04:15PM
Jun-18-23 08:58AM
Jun-07-23 08:15AM
May-22-23 07:52PM
May-13-23 08:15AM
May-11-23 10:42AM
May-09-23 07:00AM
May-03-23 04:15PM
Apr-20-23 06:15AM
Apr-17-23 08:15AM
Apr-13-23 09:01AM
Apr-05-23 06:17AM
Mar-31-23 06:36AM
Mar-27-23 07:30AM
Mar-23-23 07:00AM
03:00AM
Mar-15-23 08:00AM
Mar-08-23 05:16AM
Mar-01-23 08:15AM
Feb-15-23 07:00AM
Feb-09-23 04:15PM
Feb-03-23 09:19AM
Jan-18-23 08:25AM
Jan-12-23 05:01AM
Jan-09-23 09:25AM
09:15AM
09:05AM
08:30AM
06:35AM
Jan-04-23 04:15PM
Dec-15-22 08:15AM
Dec-08-22 05:23AM
Nov-28-22 04:26PM
Nov-09-22 08:49AM
08:10AM
Nov-08-22 07:00AM
Oct-18-22 08:30AM
Oct-17-22 08:30AM
Oct-12-22 04:15PM
07:00AM
Sep-09-22 09:15AM
Sep-06-22 04:15PM
Aug-13-22 08:05AM
Aug-04-22 07:00AM
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RIGGS RORY B Director Jan 04 '24 Sale 27.55 35,702 983,504 20,099 Jan 04 05:16 PM RIGGS RORY B Director Jan 03 '24 Sale 27.79 199,098 5,532,276 55,801 Jan 04 05:16 PM RIGGS RORY B Director Jan 02 '24 Sale 28.52 235,200 6,707,081 254,899 Jan 04 05:16 PM Avara Management Ltd 10% Owner Dec 29 '23 Sale 28.04 65,803 1,845,406 2,477,520 Jan 03 04:31 PM Avara Management Ltd 10% Owner Dec 28 '23 Sale 28.20 209,863 5,918,934 2,543,323 Dec 29 04:29 PM Avara Management Ltd 10% Owner Dec 27 '23 Sale 28.01 41,729 1,168,754 2,753,186 Dec 29 04:29 PM Avara Management Ltd 10% Owner Dec 15 '23 Sale 28.01 10,229 286,499 2,794,915 Dec 19 04:30 PM Avara Management Ltd 10% Owner Dec 14 '23 Sale 28.91 364,441 10,534,276 2,805,144 Dec 15 04:31 PM Avara Management Ltd 10% Owner Dec 13 '23 Sale 28.95 307,935 8,916,012 3,169,585 Dec 15 04:31 PM Coyne Terrance P. EVP & CFO Aug 10 '23 Sale 30.75 37,500 1,153,091 790,000 Aug 11 05:00 PM Coyne Terrance P. EVP & CFO Aug 09 '23 Sale 30.72 37,500 1,151,936 827,500 Aug 11 05:00 PM Coyne Terrance P. EVP & CFO Jul 13 '23 Sale 30.93 37,500 1,159,958 865,000 Jul 14 06:09 PM Coyne Terrance P. EVP & CFO Jul 12 '23 Sale 31.07 37,500 1,165,256 902,500 Jul 14 06:09 PM Legorreta Pablo G. CEO, Chairman of the Board Jun 28 '23 Buy 29.51 130,000 3,836,768 600,000 Jun 28 04:01 PM
Index -
P/E -
EPS (ttm) -18.35
Insider Own 32.96%
Shs Outstand 21.24M
Perf Week -15.96%
Market Cap 208.07M
Forward P/E -
EPS next Y -2.35
Insider Trans 0.00%
Shs Float 15.31M
Perf Month -51.28%
Income -285.67M
PEG -
EPS next Q -0.81
Inst Own 27.10%
Short Float 4.30%
Perf Quarter -55.06%
Sales 2.32M
P/S 89.69
EPS this Y 88.25%
Inst Trans -17.20%
Short Ratio 6.89
Perf Half Y -34.93%
Book/sh 13.24
P/B 0.69
EPS next Y 22.95%
ROA -103.26%
Short Interest 0.66M
Perf Year -43.90%
Cash/sh 1.07
P/C 8.49
EPS next 5Y -
ROE -203.41%
52W Range 8.90 - 24.61
Perf YTD -53.62%
Dividend Est. -
P/FCF -
EPS past 5Y 10.61%
ROI -61.04%
52W High -62.98%
Beta 1.93
Dividend TTM -
Quick Ratio 1.23
Sales past 5Y 837.06%
Gross Margin -332.80%
52W Low 2.36%
ATR (14) 1.01
Dividend Ex-Date -
Current Ratio 1.23
EPS Y/Y TTM 19.76%
Oper. Margin -3597.16%
RSI (14) 16.65
Volatility 9.78% 7.78%
Employees -
Debt/Eq 0.71
Sales Y/Y TTM 1289.22%
Profit Margin -12313.28%
Recom 1.67
Target Price 23.00
Option/Short Yes / Yes
LT Debt/Eq 0.68
EPS Q/Q 89.71%
Payout -
Rel Volume 2.66
Prev Close 10.03
Sales Surprise 36.25%
EPS Surprise -10.89%
Sales Q/Q 1197.62%
Earnings May 09 AMC
Avg Volume 95.66K
Price 9.11
SMA20 -33.69%
SMA50 -42.82%
SMA200 -44.91%
Trades
Volume 254,312
Change -9.17%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-09-23 Initiated
H.C. Wainwright
Buy
$25
Jul-19-23 Resumed
Canaccord Genuity
Buy
$30
Jun-12-24 08:00AM
Jun-05-24 07:00AM
May-30-24 07:00AM
May-15-24 07:00AM
May-13-24 07:00AM
10:55PM
Loading…
May-09-24 10:55PM
04:05PM
Apr-25-24 07:00AM
Mar-25-24 03:16PM
Mar-22-24 01:03PM
Mar-21-24 08:52PM
04:05PM
Mar-19-24 08:30AM
Mar-18-24 08:26AM
Mar-13-24 07:35AM
07:00AM
Loading…
Mar-07-24 07:00AM
Feb-26-24 07:00AM
Feb-07-24 12:51PM
Jan-25-24 04:30PM
Jan-17-24 07:00AM
Jan-09-24 07:00AM
Jan-04-24 07:30AM
Dec-12-23 07:30AM
Dec-01-23 08:00AM
Nov-30-23 08:00AM
Nov-09-23 04:05PM
Nov-06-23 08:00AM
Nov-02-23 04:05PM
Oct-09-23 09:33AM
Sep-18-23 05:23PM
08:00AM
Loading…
Sep-05-23 08:00AM
Aug-09-23 05:00PM
Aug-03-23 12:30PM
07:00AM
Aug-02-23 04:05PM
Jul-12-23 08:30AM
Jul-05-23 04:05PM
Jun-15-23 08:45AM
07:00AM
Jun-07-23 07:00AM
Jun-01-23 07:00AM
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded in 2010 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RIGGS RORY B Chief Executive Officer Dec 12 '23 Buy 10.58 517,107 5,470,992 1,622,495 Dec 14 05:10 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite